Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.47 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15440489 | 0.86 | HPGD (0.53) | PTK2TP53MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL9396580 | 0.85 | MEN1 (0.48) | POLBTP53MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL9398335 | 0.84 | PKM (0.47) | TP53MEN1KMT2ASMN1; SMN2TSHR | |
| SCHEMBL11636782 | 0.84 | PTK2 (0.55) | PTK2POLBTP53MEN1KMT2A | |
| SCHEMBL11578842 | 0.83 | KMT2A (0.69) | PTK2POLBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7842718 | 0.83 | TSHR (0.46) | POLBTP53MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL31469754 | 0.82 | MEN1 (0.50) | POLBTP53MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3798512 | 0.82 | RPS6KB1 (0.52) | POLBTP53MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL10734797 | 0.82 | MEN1 (0.43) | PTK2POLBTP53MEN1KMT2A | |
| SCHEMBL4063794 | 0.80 | TLR2 (0.54) | POLBTP53MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4626868-A1 | 3-PHENYLQUINAZOLINONES AS NOVEL ANTI-CANCER THERAPY | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2025-10-08 | — | — | EP | disclosed |
| WO-2024115673-A1 | 3-PHENYLQUINAZOLINONES AS NOVEL ANTI-CANCER THERAPY | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2024-06-06 | — | — | WO | disclosed |
| CN-117957218-A | Targeted protein degradation using bifunctional compounds that bind to ubiquitin ligases and target MCL-1 proteins | 凯普托尔治疗学股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| US-20230065745-A1 | PIPERIDINE-2,6-DIONE DERIVATIVES WHICH BIND TO CEREBLON, AND METHODS OF USE THEREOF | CAPTOR THERAPEUTICS S.A. (PL) | 2023-03-02 | — | — | US | disclosed |
| WO-2022253713-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | CAPTOR THERAPEUTICS S.A. (PL) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022255888-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | CAPTOR THERAPEUTICS S.A. (PL) | 2022-12-08 | — | — | WO | disclosed |
| WO-2021105335-A1 | PIPERIDINE-2, 6-DIONE DERIVATIVES WHICH BIND TO CEREBLON, AND METHODS OF USE THEREOF | CAPTOR THERAPEUTICS S.A. (PL) | 2021-06-03 | — | — | WO | disclosed |
| US-4108867-A | 2-Aminothiophenes | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1978-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230065745-A1 | PIPERIDINE-2,6-DIONE DERIVATIVES WHICH BIND TO CEREBLON, AND METHODS OF USE THEREOF | CRBN, CDR2, FABP7 | PTK2 2503/4885POLB 1886/4885TP53 3722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.